Fractyl Health, Inc. (GUTS)

In the past six months, Fractyl Health announced a proposed public offering of common stock and warrants in August 2025, followed by the closing of a $23 million underwritten public offering. In September 2025, groundbreaking data from the REMAIN-1 Midpoint Cohort showed Revita's effectiveness in maintaining weight loss after discontinuing GLP-1 drugs, leading to a stock surge, and the company announced the pricing of a $60 million underwritten offering of common stock. In October 2025, potent preclinical results from RJVA-002, a dual GIP/GLP-1 gene therapy candidate for obesity, were announced. In November 2025, the company reported its third-quarter 2025 financial results, highlighting clinical momentum for Revita and an extended cash runway into early 2027. The stock price declined by 38.33% between November 25, 2024, and November 21, 2025. Over the last 12 months, the stock's price decreased 33.01%, with a year-to-date return of -32.04%. However, in the past month leading up to November 26, 2025, the stock increased by 1.45%.

There is no explicit information available indicating demand seasonality for Fractyl Health, Inc.'s products and services. Demand is likely driven by factors such as disease prevalence, clinical trial results, regulatory approvals, market adoption, and physician and patient interest in novel therapeutic approaches, rather than seasonal patterns.

Fractyl Health, Inc. (GUTS) is a biotechnology company focused on developing therapeutic solutions for chronic metabolic diseases like type 2 diabetes (T2D) and obesity. The company operates within the healthcare sector, specifically medical/dental instruments and pharmaceuticals, aiming to address the root causes of these conditions. Its major products and platforms include the Revita DMR System, a minimally invasive procedure to modify duodenal dysfunction, and Rejuva, a virus-delivered pancreatic gene therapy platform in preclinical development.

Fractyl Health, Inc. is headquartered in Burlington, Massachusetts, United States. The Revita device is commercially available in the UK and Germany. The company aims for global expansion, seeking regulatory approvals in key markets including the United States, Europe, and Asia.

Fractyl Health's brand reputation has been influenced by both challenges and positive clinical developments over the past year. A strategic shift in January 2025 to focus Revita research on obesity and patients using GLP-1s, leading to layoffs, could have temporarily impacted its reputation. However, positive data from the REMAIN-1 Midpoint Cohort in September 2025, showing Revita's ability to maintain weight loss after GLP-1 discontinuation, bolstered confidence. Additionally, the announcement of potent preclinical results for its Rejuva gene therapy candidate in October 2025 and positive Q3 2025 results in November 2025, highlighting clinical momentum and an extended cash runway, contribute positively to its reputation.

Fractyl Health, Inc. has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors hold approximately 53.57% to 66.75% of the company's stock. Insiders own between 16.37% and 21.21%, while public companies and individual/retail investors hold approximately 1.33% to 27.29%. Major institutional owners include Nantahala Capital Management, LLC, Silverarc Capital Management, Llc, and Alyeska Investment Group, L.P.. Ajay Royan owns the most shares among individual investors, and Mithril LP is the largest individual shareholder, owning 6.41 million shares representing 4.68% of the company.